Posts Tagged ‘anxiety’

Low-Level Stress Reduced By Nature, Not Technology

Monday, July 7th, 2008

Technology can send a man to the moon, help unlock the secrets of DNA and let people around the world easily communicate through the Internet. But can it substitute for nature?
Apparently not, according to a new study that measured individuals’ heart recovery rate from minor stress when exposed to a natural scene through a window, the same scene shown on a high-definition plasma screen, or a blank wall. The heart rate of people who looked at the scene through the window dropped more quickly than the others. In fact, the high-definition plasma screen had no more effect than the blank wall.
In addition, the research done through the Human Interaction with Nature and Technological Systems Lab at the University of Washington showed that when people spent more time looking at the natural scene their heart rates tended to decrease more. That was not the case with the plasma screen.
The study, funded by the National Science Foundation, is published in the current issue of the Journal of Environmental Psychology.
"Technology is good and it can help our lives, but let’s not be fooled into thinking we can live without nature," said Peter Kahn, a UW associate professor of psychology who led the research team.
"We are losing direct experiences with nature. Instead, more and more we’re experiencing nature represented technologically through television and other media. Children grow up watching Discovery Channel and Animal Planet. That’s probably better than nothing. But as a species we need interaction with actual nature for our physical and psychological well-being."
Part of this loss comes from what the researchers call environmental generational amnesia. This is the idea that across generations the amount of environmental degradation increases, but each generation views conditions it grew up with as largely non-degraded and normal. Children growing up today in the cities with the worst air pollution often, for example, don’t believe that their communities are particularly polluted.
"This problem of environmental generational amnesia is particularly important for children coming of age with current technologies," said Rachel Severson, a co-author of the study and a UW psychology doctoral student. "Children may not realize they are not getting the benefits of actual nature when interacting with what we’re calling technological nature."
To see how people reacted to nature and a technological representation of it, the researchers recruited 90 college students to participate in an experiment that had them work on four mental tasks while sitting at a desk in an office. With 30 of the students, the desk faced a window overlooking a campus scene that included a large fountain and trees. For a second group of 30 students, the window was replaced with the plasma screen that showed the same nature scene in real time. For the remaining 30 students, curtains covered the plasma screen and the desk faced a blank wall.
Participants were tested individually. Each was welcomed by a researcher, hooked up to a heart rate monitor and told to wait for five minutes while the researcher stepped out of sight. A camera mounted on the wall near the window or plasma screen was synchronized with the heart monitor and tracked participants’ eye movements. At the end of the waiting period, the researcher returned, explained the first task and stepped out of sight. This was repeated for the remaining three tasks and then the subject was told to wait again for five minutes.
generic cialis online buy Heart recovery rate was based on how quickly each participant’s heart rate dropped in the 60 seconds after being told to wait or to have one of the tasks explained. Each person’s performance was tallied on the basis of six measurements, once after every task and the two waiting periods. Low-level stress was created by having to deal with another person in a social situation and the anticipation or performance anxiety each might have experienced to do well on the four tasks.
The researchers found that participants with the plasma screen actually looked at it just as often as did those who had the window. However, the window held the students’ attention significantly longer than the plasma screen did. When participants spent more time looking at the window, their heart rates decreased faster than on tasks when they spent less time looking at the window. This was not true with the plasma screen.
"I was surprised by this," said Kahn. "I thought the plasma screen would come somewhere between the glass window and the blank wall. This study is important because it shows the importance of nature in human lives and at least one limitation of technological nature.
"In the years ahead, technological nature will get more sophisticated and compelling. But if it continues to replace our interaction with actual nature, it will come at a cost. To thrive as a species, we still need to interact with nature by encountering an animal in the wild, walking along the ocean’s edge or sleeping under the enormity of the night sky."
—————————-
Article adapted by Medical News Today from original press release.
—————————-
Co-authors of the study are Batya Friedman, Jennifer Hagman, Erika Feldman and Anna Stolyar of the UW, Brian Gill of Seattle Pacific University, Nathan Freier of Rensselaer Polytechnic Institute and Sybil Carr??»re of California State University, San Bernardino. Freier and Carr??»re were both at the UW when they worked on the study.
More information about the Human Interactions with Nature and Technological Systems Lab is available at
Source: Joel Schwarz
University of Washington
generic fosamax online buy | Generic acomplia pills no prescription | Generic diflucan pills no prescription

Maximum Life’s Product Navitol Clinically Proven To Reduce Systolic Blood Pressure

Sunday, July 6th, 2008

For Health Professionals
Latest News For Hypertension
CocoaVia Dark Chocolate Bars Shown To Lower Cholesterol
22 Apr 2008
Electronic Handheld Blood Pressure Devices Market To Reach 793 Million Dollars By 2010, According To New Report By Global Industry Analysts, Inc.
22 Apr 2008
New Antihypertensive PritorPlus® 80/25 And Kinzalkomb® 80/25 Approved By EU Commission
21 Apr 2008
View more news…
Latest Videos for Hypertension
Medications and Diet for hypertension
Hypertension or high blood pressure is a risk factor for heart disease, stroke and other cardiovascular conditions. Fortunately, it can be controlled. Tune in to find out how…
Diabetes and Hypertension
Controlling blood sugar levels are crucial for people with diabetes. But equally important is blood pressure control. generic propecia online buy High blood pressure and diabetes often occur together and if left untreated can lead to serious consequences. Join experts as they discuss the link between these two conditions, who…
View more videos…
Advertisements
Add Your Advertisement Here
Most Popular Categories
public health
neurology
nutrition
cancer
cardiovascular
hiv
diabetes
dermatology
obesity
alcohol
psychology

women’s health
infectious diseases
pediatrics
breast cancer
urology
pregnancy
gastrointestinal

pain
respiratory
prostate
bones
depression
smoking
medical devices
health insurance
medicare
hypertension
stem cell research
biology
alzheimer’s
sexual health
sleep
abortion
genetics
allergy
autism
eye health
adhd
it
multiple sclerosis
sports medicine
pharma industry
dentistry
liver disease
anxiety
arthritis
seniors

cholesterol
mrsa
Buy cialis without prescription | Buy propecia pills | Buy levitra without prescription

Gene/Stress Interaction Increases Cognitive Decline In Elderly

Friday, July 4th, 2008

The negative effects of stress on cognitive functioning appear to be amplified by a genetic variation associated with Alzheimer’s disease, a new federally funded study has found. The genetic variation may, in effect, accelerate the development of age-related cognitive decline by as much as eight years.
Researchers from the Baltimore Memory Study report in The American Journal of Psychiatry (AJP), the official journal of the American Psychiatric Association, that a high level of the stress hormone cortisol in study participants aged 50 to 70 years was associated with worsened cognitive abilities. The researchers also found that the effect was greater among those with a common form of the gene for apolipoprotein E (APOE), which has been shown to increase the risk for Alzheimer’s disease.
This gene-environment interaction is reported by Brian Lee, M.H.S., Brian Schwartz, M.D., and colleagues at Johns Hopkins University. The group’s findings will be presented online on July 1 under AJP in Advance .
The effect appears to increase as the number of copies of a specific APOE gene in the individual increases. Everyone inherits two versions of the APOE gene, known as alleles - one from each parent. The most common APOE alleles are epsilon-2, -3, and -4. Having at least one epsilon-4 allele increases an individual’s risk of late-onset Alzheimer’s disease. Individuals with two copies of the esiplon-4 version of the gene are particularly susceptible to the damaging effects of cortisol in the brain.
"Our findings indicate that the APOE epsilon-4 allele may increase vulnerability of the aging brain to elevated cortisol levels," said lead author Lee, a doctoral student in epidemiology at the Johns Hopkins Bloomberg School of Public Health. "While our results remain to be replicated, the observed cortisol-APOE interaction is intriguing since both cortisol and APOE have been implicated in cognitive decline associated with aging as well as in Alzheimer’s disease."
The effects on cognitive functioning extended to six of the seven areas that were studied: language, eye-hand coordination, executive functioning, verbal memory/learning, visual memory, and ability to copy a complex visual design.
Buy generic zithromax The deficits are similar in magnitude to those seen with advancing age. The authors estimated the equivalent years of increased age, represented by the poorer cognition of the study participants with high cortisol and the epsilon-4 form of the APOE gene. For language ability, the lower scores of people with high cortisol levels and one epsilon-4 copy were comparable to an age increase of eight years. For those with two epsilon-4 copies, the comparable age increase was even larger.
The study was supported by the National Institute on Aging and the National Institutes of Health Division of Research Resources.
Reference
Lee BK, Glass TA, Wand GS, McAtee MJ, Bandeen-Roche K, Bolla KI, Schwartz BS: Apolipoprotein E Genotype, Cortisol and Cognitive Function in Community-Dwelling Older Adults. Am J Psychiatry (published online July 1, 2008; doi: 10.1176/appi.ajp.2008.07091532)
About the American Journal of Psychiatry
The American Journal of Psychiatry is the official journal of the American Psychiatric Association. Statements in this press release or the articles in the Journal are not official policy statements of the American Psychiatric Association. AJP in Advance is a regular online feature where original research articles accepted for publication in The American Journal of Psychiatry are posted online in advance of their appearance in print.
About the American Psychiatric Association
The American
Psychiatric Association is a national medical specialty society whose more than 38,000 physician members specialize in diagnosis, treatment, prevention and research of mental illnesses including substance use disorders. Visit the APA at and
American Psychiatric AssociationGeneric cipro pills no prescription | Generic soma pills no prescription | Generic ultram pills no prescription

European CHMP Issues Positive Opinion On Cymbalta For The Treatment Of Generalised Anxiety Disorder

Saturday, June 28th, 2008

Eli Lilly and Co (NYSE:
LLY) and Boehringer Ingelheim announced that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency
(EMEA) has issued a positive opinion supporting the approval of Cymbalta(R)
(duloxetine hydrochloride) for the treatment of Generalised Anxiety
Disorder (GAD).
The positive opinion is based upon the results of five clinical studies
– four double-blind placebo-controlled studies and a relapse prevention
study — involving more than 2,000 non-depressed adults with GAD. In each
of the four placebo-controlled studies safety and efficacy were assessed.
Duloxetine significantly improved core anxiety symptoms (as measured by the
Hamilton Anxiety Scale), compared with placebo (p less than or equal to
0.001, p=0.02, p=0.007, p less than or equal to 0.001 respectively)
(1,2,3,4) and demonstrated improvement in role functioning, including
ability to
perform everyday activities in work, home and in social
situations.(5,6) In addition, duloxetine significantly decreased the
likelihood of relapse in those patients who initially responded to
duloxetine and were maintained on treatment for six months compared with
those switched to placebo.(7) The most common side effects in these studies
included nausea, fatigue, dry mouth, drowsiness, constipation, insomnia,
decreased appetite, hyperhidrosis, decreased libido, vomiting, ejaculation
delay and erectile dysfunction.
Although global prevalence is not currently known, more than nine
million Europeans (8,9) and six million people in Central and South America
are estimated to suffer from GAD.(10) Difficult to detect, due to the fact
that the condition presents with a variety of symptoms,(11) GAD is
characterised by more than simple anxiety. The disorder is diagnosed when
patients suffer from excessive anxiety and worry about a number of events
and activities (such as performance at work or school) over a sustained
period of at least six months.(12)
"If left untreated, symptoms of Generalised Anxiety Disorder may
progress to prevent patients from working and operating in daily social
situations," said Dr. Christer Allgulander of the Department of Clinical
Neuroscience, Karolinska Institutet in Stockholm. "According to population
and primary care surveys the majority of people suffering from anxiety, and
their physicians, still have unmet needs. This positive opinion on
duloxetine creates another effective pharmacotherapy option that will help
patients feel better, and help physicians in their aim to improve
functioning for those suffering from this debilitating condition."
Duloxetine, a member of a class of drugs commonly referred to as
serotonin and noradrenaline reuptake inhibitors,(13) is already approved to
treat major depressive disorder and diabetic peripheral neuropathic pain.
Duloxetine gained marketing authorisation for the treatment of GAD in
Mexico in 2006 and in the United States in 2007.
About Generalised Anxiety Disorder
Approximately nine million Europeans (8,9) and six million people in
Central and South America are estimated to suffer from GAD.(10) Quality of
life
is affected as symptoms of GAD can include exaggerated worry or
chronic anxiety, irritability and poor concentration. Ability to work is
often compromised with the manifestation of physical symptoms such as
muscle tension, fatigue, sleep disturbance and nausea.(12) The illness
tends to be chronic with periods of exacerbation and remission. Patients
report that episodes of generalized anxiety disorder are often brought on,
or worsened, by stressful life events.(14)
About Duloxetine
While duloxetine’s mechanism of action in humans is not fully known, it
is believed to affect both serotonin and norepinephrine/noradrenaline
mediated nerve signalling in the brain and the spinal cord. Based on
pre-clinical studies, duloxetine is a balanced and potent reuptake
inhibitor of serotonin and norepinephrine/noradrenaline. Scientists believe
its effect on pain perception is due to increasing the activity of
serotonin and norepinephrine in the central nervous system.
Duloxetine is approved for the treatment of depression and diabetic
peripheral neuropathic pain, in many countries and is approved in some
countries for the treatment of stress urinary incontinence, Major
Depressive Disorder and Generalized Anxiety Disorder. Duloxetine is
approved only for adults 18 and over. There is a possibility of an
increased risk of suicidal thoughts or behaviour in children and young
adults treated with antidepressants. Patients should call their doctor
right away if they experience worsening depression symptoms, unusual
changes in behaviour or thoughts of suicide, especially at the beginning of
treatment or after a change in dose.
Patients taking duloxetine may experience dizziness or fainting upon
standing. The most common side effects of duloxetine include:
– For depression: Nausea, dry mouth, headache, insomnia, diarrhea
– For diabetic peripheral neuropathic pain: Nausea, somnolence
(sleepiness), fatigue, headache, dizziness
– For stress urinary incontinence: Nausea, dry mouth, fatigue
– For Generalised Anxiety Disorder: Nausea, fatigue, dry mouth,
drowsiness, constipation, insomnia, decreased appetite, hyperhidrosis,
decreased libido, vomiting, ejaculation delay and erectile dysfunction.
Duloxetine is contraindicated in patients who are allergic to it, who
have liver disease resulting in hepatic impairment, who are taking a
monoamine oxidase inhibitor (MAOI), fluvoxamine, ciprofloxacin or enoxacine
or who have severe kidney disease. The initiation of treatment with
duloxetine also is contraindicated in patients with uncontrolled
hypertension that
could expose them to a potential risk of hypertensive
crisis.
Eli Lilly and Company and Boehringer Ingelheim
In November 2002, Eli Lilly and Company and Boehringer Ingelheim signed
a long-term agreement to jointly develop and commercialize duloxetine
hydrochloride. This partnership covers neuroscience indications in most
countries outside of the United States and Japan, with few exceptions.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of best-in-class pharmaceutical products by applying the latest
research from its own worldwide laboratories and from collaborations with
eminent scientific organizations. Headquartered in Indianapolis, Ind.,
Lilly provides answers - through medicines and information - for some of
the world’s most urgent medical needs. Additional information about Lilly
is available at
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates
globally with 135 affiliates in 47 countries and almost 38,900 employees.
Since it was founded in 1885, the family-owned company has been committed
to researching, developing, manufacturing and marketing novel products of
high therapeutic value for human and veterinary medicine. In 2007,
Boehringer Ingelheim posted net sales of 10.9 billion euro while spending
one fifth of net sales in its largest business segment Prescription
Generic ultram pills no prescription Medicines on research and development. For more information please visit

Duloxetine for major depressive episodes is marketed by Lilly and
Boehringer Ingelheim in all countries included in the partnership under the
brand name Cymbalta, except for Greece, Italy and Spain. In Greece, Italy
and Spain Lilly markets the product as Cymbalta and Boehringer Ingelheim
markets the product as Xeristar(R). In the United States, Cymbalta is
marketed by Lilly and Quintiles. In Japan, duloxetine will be co-developed
and co-marketed by Lilly and Shionogi & Co., Ltd.
Duloxetine for stress urinary incontinence is marketed by Lilly under
the brand name Yentreve.(R)
References
(1) Koponen, H., et al. Efficacy of Duloxetine for the Treatment of
Generalized Anxiety Disorder: Implications for Primary Care Physicians.
Prim Care Companion J Clin Psychiatry 2007: 9(2):100-107
(2) Rynn M., et al. Efficacy and Safety of Duloxetine in the Treatment
of Generalized Anxiety Disorder: A Flexible-Dose, Progressive-Titration,
Placebo- Controlled Trial. Depression and Anxiety 2007: 25(3): 182-189.
(3) Hartford, J., et al. Duloxetine as an SNRI Treatment for
Generalized Anxiety Disorder: Results from a Placebo- and Active-Controlled
Trial. Int Clin Psychopharmacol 2007: 22(3):167-74.
(4) Nicolini H, et al. Improvement of psychic and somatic symptoms in
adult patients with generalized anxiety disorder: Examination from a
duloxetine, venlafaxine extended-release, and placebo-controlled study. In
Press at Psychological Medicine.
(5) Endicott, J., et al. Duloxetine Treatment for Role Functioning
Improvement in Generalized Anxiety Disorder: Three Independent Studies. The
Journal of Clinical Psychiatry 2007: 68(4):518-24
(6) Allgulander, C., et al. Pharmacotherapy of Generalized Anxiety
Disorder: Results of Duloxetine Treatment from a Pooled Analysis of 3
Clinical Trials. Current Medical Research and Opinion 2007: 23(6):
1245-1252
(7) Davidson JRT, et al. Duloxetine treatment for relapse prevention in
adults with generalized anxiety disorder: A 26- week randomized
placebo-controlled study. Poster presented at the American College of
Neuropsychopharmacology annual conference 2007. Boca Raton, Florida
(8) Lieb, R, et al. The epidemiology of generalised anxiety disorder in
Europe. European Neuropsychopharmacology 2005 Aug;15(4):445-52.
(9) National Institute of Economic and Social Research. Summarized from
the National Institute Economic Review,194, 28 October 2005.
(10) Calculated extrapolations of prevalence rates against the
populations of a particular country or region, based upon prevalence of
generalized anxiety disorder in the US, UK, Canada or Australia. Available
at:
Accessed on 2.4.08
(11) Gliatto, M.F. Generalised Anxiety Disorder. American Family
Physicians, Vol. 62/No. 7, October 1, 2000.
(12) National Institute of Mental Health (NIMH). Anxiety Disorders.
Available at:
Accessed on 2.5.08
(13) Bymaster, FP et al. The Dual Transporter Inhibitor Duloxetine: A
Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and
Clinical Results in Depression. Current Pharmaceutical Design. 2005; 11:
1475-1493.
(14) Patient.co.uk. Generalized anxiety disorder. Available at
Accessed on 2.5.08
Eli Lilly and Company

View drug information on Cymbalta.
Generic cialis pills no prescription | Buy generic viagra | Buy generic cipro

Department Of Defense, HHS Announce Program To Send Mental Health Care Professionals To Help Soldiers With PTSD

Tuesday, June 24th, 2008

Department of Defense and HHS officials on Wednesday announced a program under which the departments will send 200 psychiatrists, social workers and other mental health care professionals to military facilities to treat the increased number of soldiers who have post-traumatic stress disorder, the Washington Times reports.
Adm. Joxel Garcia, assistant secretary for health at HHS, said that the program will coordinate scientific research for the mental health care needs of soldiers and improve treatment and prevention efforts for PTSD. Garcia said, "We are very proud that this is an effort to essentially serve not only the veterans that are coming from war, but also their families."
S. Ward Casscells, assistant DOD secretary for health affairs, said, "The cavalry riding to the rescue is the public health service." He added that the departments might decrease the number of mental health care professionals sent under the program to 100, as the current number assumes "that there would be a surge of people asking for mental counseling and psychological counseling" because of efforts to "reduce the stigma of asking for help, to assure people that this won’t adversely impact their career" (Hudson, Washington Times, 6/5).
Reprinted with kind permission from You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.
© 2008 Buy soma without prescription Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Generic lasix pills no prescription | Buy generic levitra | Buy generic cipro